Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Abbott LaboratoriesNYSE: ABT

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $1.01B rose 30.4% year over year, ahead of the +5.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 38.8% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • Depreciation & amortization amounted to 7.0% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +30.4% holds above the trailing-twelve-month pace of +5.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.01B+38.8% QoQ
Last fiscal yearDec 2025
$3.12B-3.2% YoY
LTMJun 2026
$3.33B+5.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.4%——
1 year-3.2%——
3-year CAGR-1.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
3.12B USD
Year-over-year change
-3.2%
4-year CAGR
-3.1%

Depreciation & Amortization vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's LTM Jun 2026 depreciation & amortization of $3.33B is the 2nd largest of the 10 companies compared; the peer median is $1.91B.
  • Its year-over-year change of +5.9% is the 7th highest of 10, against a peer median of +7.5%.
  • Depreciation & amortization amounts to 7.1% of revenue for ABT, versus a peer median of 6.7%.
ABT Competitors Peer median
Depreciation & Amortization for ABT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$8.09B +9.5%+2.5%8.1%
ABTAbbott LaboratoriesLTM Jun 2026$3.33B +5.9%-1.6%7.1%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
MDTMedtronic plcLTM Jul 2026$2.85B -3.4%+3.1%7.6%
BDXBecton, Dickinson and CompanyLTM Sep 2026$2.24B -4.2%-0.7%11.1%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
BSXBoston Scientific CorporationLTM Jun 2026$1.41B +7.5%+6.4%6.7%
SYKStryker CorporationLTM Jun 2026$1.25B +13.3%+6.1%4.8%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$607M +7.1%-3.0%3.0%
EWEdwards Lifesciences CorporationLTM Jun 2026$165.5M +9.0%+3.9%2.5%
Peer median (excluding ABT) $1.91B+7.5%+3.1%6.7%

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.07B6.93B5.72B13.4B6.52B
Depreciation & Amortization3.54B3.27B3.24B3.22B3.12B
Deferred Income Tax00000
Stock-Based Compensation640M685M644M673M664M
Change in Working Capital(771M)(1.52B)(2.48B)(9.22B)(803M)
Accounts Receivables(383M)(68M)(356M)(691M)(652M)
Inventory(456M)(1.41B)(232M)(58M)195M
Accounts Payables1.29B420M(760M)356M954M
Other Working Capital(1.22B)(458M)(1.13B)(8.82B)(1.3B)
Other Non-Cash Items55M215M126M482M65M
Operating Cash Flow10.53B9.58B7.26B8.56B9.57B
Capital Expenditures(1.89B)(1.78B)(2.2B)(2.21B)(2.17B)
Acquisitions (Net)(53M)48M(837M)1M(105M)
Purchases of Investments(173M)(185M)(159M)(169M)(167M)
Sales of Investments77M152M43M28M3M
Other Investing Activities26M22M22M9M18M
Investing Cash Flow(2.01B)(1.74B)(3.13B)(2.34B)(2.42B)
Debt Repayment(248M)(699M)(2.48B)(537M)(1.61B)
Common Stock Issued0000396M
Common Stock Repurchased(2.3B)(3.8B)(1.23B)(1.3B)(893M)
Dividends Paid(3.2B)(3.31B)(3.56B)(3.84B)(4.12B)
Other Financing Activities255M167M167M264M(82M)
Financing Cash Flow(5.49B)(7.64B)(7.09B)(5.4B)(6.31B)
Effect of Forex Changes(70M)(122M)(23M)(96M)71M
Net Change in Cash2.96B83M(2.99B)720M906M
Free Cash Flow8.65B7.8B5.06B6.35B7.4B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.